news

Announcements and Updates


TOLREMO therapeutics AG – Preventing Drug Resistance in Cancer Therapy

TOLREMO therapeutics AG – Preventing Drug Resistance in Cancer Therapy

Zürich, September 18th 2017. TOLREMO therapeutics AG (“TOLREMO”), a privately held research-stage biotechnology company, announced today the completion of a fundraiser with private investors of 2.4 million Swiss Francs. The proceeds will be used to advance the company’s discovery and development of breakthrough medicines to target drug resistance in cancer therapy.

Dr. Stefanie Flückiger-Mangual, Chief Executive Officer and co-founder of TOLREMO, commented: “Cancer patients often respond favorably to modern therapies, but in many cases long-term survival is limited by the development of drug resistance. During several years of research at ETH Zurich, we discovered that, surprisingly, the development of drug resistance already starts early on following initiation of cancer therapy. We have developed a deep understanding of the molecular mechanisms involved in this and our goal is to intervene with these mechanisms in order to eradicate the seed of drug resistance and extend patient survival.”

TOLREMO’s science-based drug discovery and development pipeline is fueled by a unique drug screening platform for which a patent has been filed. In addition to discovering and developing novel anti-drug resistance molecules, the platform is also used to identify novel ways of combining approved drugs to prevent drug resistance in cancer therapy.

Dr. Isaac Kobrin, Chairman of the Board and a co-founder of TOLREMO, commented: “We believe that TOLREMO is poised to reach several key milestones in the development of novel cancer therapies within the next 12 to 18 months. The currently raised funds of 2.4 million Swiss Francs are expected to cover that period and prepare the grounds for the future growth of the company.”

TOLREMO is an ETH Spin-off and was founded in March 2017. The company is headquartered on the ETH Hönggerberg campus in Zurich, Switzerland, where it is part of a dynamic scientific and entrepreneurial community. TOLREMO enjoys broad access to state- of-the art ETH infrastructure including laboratory space and an industry standard robotic screening facility.

TOLREMO therapeutics AG I c/o ETH Zurich I Molecular Health Sciences I HPL H16.2 I Otto-Stern-Weg 7 I 8093 Zurich I Switzerland www.tolremo.com

Successful first financing round allows ETH Spin-off to advance drug discovery

and development efforts

About the Management and Board of TOLREMO

Dr. Stefanie Flückiger-Mangual: co-founder, Chief Executive Officer and board member. PhD from ETH Zurich in Molecular and Translational Biomedicine. Led the team of scientists who discovered novel drug resistance mechanisms in cancer.

Mr. Emmanuel Savioz: co-founder, Chief Financial Officer and board member. MBA from Haas School of Business, UC Berkeley. Co-founder of Phi Pharma SA, HYT SA and Preciflex SA. Previously, investment banker in M&A in New York.

Dr. Isaac Kobrin: co-founder and Chairman of the board. Former international group leader at Roche responsible for the worldwide clinical development of key cardiovascular compounds from Phase I to market approval. In his last position, Head of Clinical Development and Chief Medical Officer of Actelion Pharmaceuticals Ltd.

Prof. Dr. Wilhelm Krek: co-founder and board member. ETH Full Professor of Cell Biology and Head of the Cell Signaling and Disease Biology Laboratory. Co-founder of the ETH Spin-off ProteoMediX AG.

Prof. Dr. Karl-Heinz Altmann: co-founder & board member. ETH Full Professor of Pharmaceutical Sciences. Current Head of Department of Chemistry and Applied Biosciences at ETH Zurich. After 13 years of experience in Pharma industry, he was last acting as Global Head of Chemistry at Novartis Institutes for BioMedical Research (NIBR).

Contact

info@tolremo.com

TOLREMO therapeutics AG I c/o ETH Zurich I Molecular Health Sciences I HPL H16.2 I Otto-Stern-Weg 7 I 8093 Zurich I Switzerland www.tolremo.com